BIOLASE and Cefla Dental Group Announce Exclusive Distribution Agreement
23 Febrero 2012 - 8:00AM
Marketwired
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, and Cefla Dental Group, a
leading Italian dental equipment manufacturer, today announced that
the companies have entered a definitive three-year agreement making
BIOLASE a distributor of Cefla's NewTom Cone Beam 3D imaging
products in the U.S. and Canada. The NewTom products are well
respected in the medical and dental communities and considered
among the highest quality 3D dental imaging products in the world.
Under the terms of the agreement, BIOLASE will be the exclusive
distributor for dentists, dental schools and dental clinics, and
non-exclusive for certain other medical markets.
NewTom's Cone-Beam-Computed-Tomography (CBCT) is a compact
version of standard CT imaging that uses a cone-shaped X-ray beam
to obtain a multitude of radiographs that construct digital 3D
models of maxillofacial anatomies. Some of the advantages compared
to traditional CT scanners include less radiation, faster scan
times and a more comfortable patient experience.
The NewTom 3D imaging products are typically used in highly
complex dentistry cases by periodontists, endodontists and oral
surgeons where more involved and higher accuracy images are needed.
They are increasingly being adopted by general practitioners for
use in placing implants. The current installed base of NewTom in
North America and worldwide is approximately 300 and 900 products,
respectively.
The combination of the BIOLASE installed base of more than
19,000 lasers among 16,000 customers, brand recognition and
marketing expertise with the NewTom reputation for quality and
performance was the driving force for the agreement, said Sergio
Ghezzi, global managing director of Cefla Dental's NewTom imaging
division.
"We have made a strong commitment to establish ourselves as a
substantial competitor in the North American 3D CBCT imaging market
and consider BIOLASE an ideal partner to accomplish that goal,"
Ghezzi said. "Working closely with BIOLASE, we believe we can
sustain growth in our NewTom U.S. business unit while bringing the
dental community the highest quality 3D imaging products in the
world."
Federico Pignatelli, BIOLASE Chairman and CEO, noted that the
NewTom products will nicely complement the state-of-the-art BIOLASE
DaVinci Imaging™ dental imaging devices and provide dental
customers a wider and more comprehensive choice of configurations,
range of performance and price points.
"The NewTom CBCT is widely known as the finest 3D imaging unit
in the world," Pignatelli said. "NewTom is a great brand and a
great technology with market-leading products which will nicely
augment our suite of highly respected, advanced imaging products
and market leading lines of diode and all-tissue lasers. We've
named this integration of lasers and imaging the Total Technology
Solution with the motto, 'See More-Do More.' The better the 3D
imaging capabilities of the dental professional, the earlier the
diagnosis and the more indications that can be identified and
treated minimally invasively with our Waterlase iPlus™ and iLase™
laser technologies, in many cases without the use of anesthesia, in
a very biologically friendly fashion.
"This partnership is a nice fit for both companies including
select other international markets and should also provide us with
an entryway into a new and expansive source of revenue from the
periodontic, endodontic and oral surgery markets," Pignatelli
concluded.
The NewTom Cone Beam 3D imaging products will be featured in
BIOLASE's Booth (#1237) at the annual Chicago Dental Society
Midwinter Meeting being held February 23-25.
About Cefla Dental Group The company
manufactured the world's first CBCT scanner in 1997 and NewTom has
since become the global leader in maxillofacial and medical CBCT
application technology. Located in Verona, Italy, NewTom is part of
Cefla s.c., a market leader in production and marketing of a wide
range of dental brands such as treatment center and chair lines
Anthos, Castellini, SternWeber and Victor, as well as imaging
brands NewTom and MyRay. For more information, readers are
encouraged to visit www.newtom.us or call the company at
+1-704-731-5293.
About BIOLASE Technology, Inc. BIOLASE
Technology, Inc., the World's leading Dental Laser Company, is a
medical technology company that develops, manufactures and markets
dental lasers and also distributes and markets dental imaging
equipment, products that are focused on technologies that advance
the practice of dentistry and medicine. The Company's laser
products incorporate 284 patented and patent pending technologies
designed to provide clinically superior performance with less pain
and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. Other products under
development address ophthalmology and other medical and consumer
markets.
For updates and information on laser and Waterlase dentistry,
find BIOLASE at http://www.biolase.com, Twitter at
http://twitter.com/GoWaterlase, and YouTube at
http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within
the meaning of safe harbor provided by the Securities Reform Act of
1995 that are based on the current expectations and estimates by
our management. These forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," and variations of these words or similar expressions.
Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks, uncertainties
and other factors which may cause the Company's actual results to
differ materially from the statements contained herein, and are
described in the Company's reports it files with the Securities and
Exchange Commission, including its annual and quarterly reports. No
undue reliance should be placed on forward-looking statements. Such
information is subject to change, and we undertake no obligation to
update such statements.
For further information, please contact: Jill Bertotti Allen
& Caron +1-949-474-4300 jill@allencaron.com Sandra Stein Cefla
Dental +1-704-731-5279 Sandra.Stein@cefladental.com
Biolase (NASDAQ:BLTI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biolase (NASDAQ:BLTI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024